Bevacizumab,Durvalumab,Olaparib,Carboplatin,Paclitaxel
AstraZeneca,roche,Merck
['imfinzi', 'brca', 'lynparza', 'ovarian']
a major need in ovarian cancer is being met: data from #asco23 shows an imfinzi/lynparza combo can significantly slow progression of advanced disease without the brca mutation. dr. merry markham calls this "meaningful progress." 
The trusted source for information on cancer built in collaboration with millions of patients and the country's leading academic medical centers.